2020
DOI: 10.1111/dth.14169
View full text
|
Sign up to set email alerts
|
Share

Abstract: While dupilumab has emerged as an effective treatment for moderate-to-severe atopic dermatitis (AD) since its approval, interleukin (IL)-4 and 13 blockade has also demonstrated efficacy in off-label chronic dermatologic conditions, such as alopecia areata (AA). 1,2 Recently, cases of dupilumab-induced phenotype switching from AD to psoriasis have been reported. 3,4 Here, we present three cases of new psoriasis onset under dupilumab treatment: two patients affected by AD and one patient affected by AA. I. D'Amb…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
5
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals